Bisphosphonates in common pediatric and adult bone sarcomas - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles BONE Year : 2020

Bisphosphonates in common pediatric and adult bone sarcomas


The therapeutic strategies proposed currently for bone sarcomas are based on neo-adjuvant chemotherapy, delayed en-bloc wide resection, and adjuvant chemotherapy. Unfortunately, bone sarcomas are characterized by high rates of poor drug response, with a high risk of drug resistance, local recurrence and/or a high propensity for induced metastases. The pathogenesis of bone sarcomas is strongly associated with dysregulation of local bone remodeling and increased osteolysis that plays a part in tumor development. In this context, bisphosphonates (BPs) have been proposed as a single agent or in combination with conventional drugs to block bone resorption and the vicious cycle established between bone and sarcoma cells. Pre-clinical in vitro studies revealed the potential "anti-tumor" activities of nitrogen-bisphosphonates (N-BPs). In pre-clinical models, N-BPs reduced significantly primary tumor growth in osteosarcoma and Ewing sarcoma, and the installation of lung metastases. In chondrosarcoma, N-BPs reduced the recurrence of local tumors after intralesional curettage, and increased overall survival. In pediatric and adult osteosarcoma patients, N-BPs have been assessed in combination with conventional chemotherapy and surgery in randomized phase 3 studies with no improvement in clinical outcome. The lack of benefit may potentially be explained by the biological impact of N-BPs on macrophage differentiation/recruitment which may alter CD8+-T lymphocyte infiltration. Thanks to their considerable affinity for the mineralized extracellular matrix, BPs are an excellent platform for drug delivery in malignant bone sites with reduced systemic toxicity, which opens up new opportunities for their future use.
Fichier principal
Vignette du fichier
Heymann MF et al Bone 2020 rev+Tab (2).pdf (802.67 Ko) Télécharger le fichier

Dates and versions

inserm-03298321 , version 1 (23-07-2021)



Marie-Francoise Heymann, Frederic Lezot, Dominique Heymann. Bisphosphonates in common pediatric and adult bone sarcomas. BONE, 2020, 139, pp.115523. ⟨10.1016/j.bone.2020.115523⟩. ⟨inserm-03298321⟩
21 View
197 Download



Gmail Facebook Twitter LinkedIn More